How to Prevent Alzheimer’s Disease + 8 Strategies That Actually Have Evidence Behind Them

Let me start with the sentence most articles bury: there is no pill, diet, or supplement that guarantees you will never develop Alzheimer’s disease. Anyone who tells you otherwise is selling something.

But that is not the same as saying nothing works. In 2024, the Lancet Commission on dementia prevention concluded that roughly 45% of dementia cases worldwide are linked to 14 modifiable risk factors — things you can actually do something about. That figure is a population estimate, not a personal guarantee. Still, it reframes the question. The realistic goal is not immunity. It is compressing the years you might spend with dementia into a shorter window, later in life, and buying yourself more good years first.

What Alzheimer’s Actually Is (And What It Isn’t)

Alzheimer’s disease is the most common cause of dementia, accounting for roughly 60–70% of cases. It is a biological disease defined by two abnormal protein changes in the brain: amyloid-beta plaques that accumulate between neurons, and tau tangles that build up inside them. These changes begin 15 to 20 years before the first symptom appears.

Read that last sentence again, because it is the whole basis for prevention. By the time someone forgets a grandchild’s name, the underlying process has been running for two decades. If you are 45 and reading this, the biology you influence today is the biology that determines your cognition at 70.

A few clarifications that come up constantly in clinic:

Alzheimer’s is not normal aging. Occasionally forgetting where you parked is normal. Forgetting that you drove is not. Normal aging slows retrieval you eventually remember the name. Alzheimer’s erases the encoding Dementia is the syndrome (cognitive decline sever Dementia is the syndrome (cognitive decline severe enough to impair daily life). Alzheimer’s is one cause. Others include vascular dementia, Lewy body dementia, and frontotemporal dementia and mixed pathology is extremely common in people over 80.

Prevalence context: About one-third of people aged 85 and older have clinical Alzheimer’s dementia, according to the Alzheimer’s Association’s Facts and Figures report. Around 5% of cases are early-onset, appearing before age 65. So yes, it happens in younger people but it is uncommon, and the vast majority of early-onset cases are not the rare inherited form.

similar article: Body Tremors + What They Mean and 7 Evidence-Based Treatment Approaches

Who Is at Risk — and How Much of It Is Genetic

This is where the original version of most Persian-language health articles goes badly wrong. The claim that “the most important factor is a mutation in specific brain genes, so prevention is impossible” is both factually incorrect and actively harmful, because it tells readers their choices don’t matter.

Here is the accurate picture:

Deterministic (autosomal dominant) Alzheimer’s — caused by mutations in APP, PSEN1, or PSEN2 — accounts for *wellP, PSEN1, or PSEN2 — accounts for well under 1% of all cases. These families typically show onset in the 30s, 40s, or 50s across multiple generations. If that diet article.

Risk-modifying genetics — primarily APOE ε4 — is a different thing entirely. Carrying one copy raises lifetime risk roughly 2–3 fold; two copies raise it more substantially. But this is probability, not destiny: many ε4 carriers never develop dementia, and many people with Alzheimer’s carry no ε4 allele at all. Importantly, in the US POINTER trial published in JAMA in 2025, lifestyle intervention benefits held regardless of APOE ε4 status. Genetics does not cancel out effort.

Non-modifiable factors: age (the dominant one), family history, Down syndrome, and female sex (partly explained by longevity, though not entirely).

The 14 modifiable factors identified by the 2024 Lancet Commission, grouped by when they matter most:

High LDL cholesterol and untreated vision loss were added in the 2024 update — they were not in the 2020 report. This is a field that moves, which is one reason a 2022 article on this topic is now meaningfully out of date.

The 8 Evidence-Based Prevention Strategies

I have ordered these by strength of evidence and size of likely effect not by how interesting they sound. The boring ones are the ones that work.

1. Treat Hearing Loss — The Single Largest Modifiable Factor

If you take one thing from this article, take this. In the Lancet Commission’s modeling, hearing loss carries the largest population-attributable fraction of any single modifiable risk factor (~7%) — larger than smoking, larger than physical inactivity.

Why would hearing affect the brain? Three plausible mechanisms, likely operating together: degraded auditory input reduces cognitive stimulation; straining to hear diverts cognitive resources away from memory encoding; and hearing loss drives social withdrawal, which is itself a risk factor.

What the trial evidence actually shows — and this is where honesty matters. The ACHIEVE trial (Lancet, 2023; N=977) randomized older adults to hearing intervention versus health education. Over three years, there was no significant difference in global cognition in the overall cohort. However, in the pre-specified subgroup at higher baseline risk — the 238 participants recruited from the ARIC cardiovascular cohort — hearing intervention was associated with roughly a 48% reduction in the rate of cognitive decline.

How to interpret that: the effect appears real but concentrated in people who are already vulnerable. It is not proven that hearing aids protect a healthy 65-year-old’s cognition. It is reasonably well supported that treating hearing loss in someone with cardiovascular risk factors and existing hearing impairment slows decline. Given that hearing aids are safe, improve quality of life immediately, and reduce isolation, the risk-benefit calculation is straightforward even with imperfect evidence.

Practical: Get a baseline audiogram at 50. Repeat every 2–3 years. If you find yourself turning up the TV, asking people to repeat themselves in restaurants, or avoiding group conversations — get tested now, not in five years. Over-the-counter hearing aids have made this dramatically more accessible.

2. Protect Your Blood Vessels — Blood Pressure, LDL, and Glucose

Your brain consumes about 20% of your cardiac output through vessels that are, in places, a few cells wide. Vascular damage and Alzheimer’s pathology are not separate diseases competing for the same patient; they compound each other. Most dementia in people over 80 is mixed.

Blood pressure is the best-evidenced target. The SPRINT MIND trial (JAMA, 2019) randomized over 9,000 hypertensive adults to intensive systolic targets (<120 mmHg) versus standard (<140 mmHg). Intensive control produced a statistically significant 19% reduction in mild cognitive impairment and a reduction in the combined MCI-plus-dementia endpoint. The dementia-alone endpoint did not reach significance — the trial stopped early for cardiovascular benefit, leaving it underpowered for that outcome. Long-term follow-up has strengthened the picture.

Midlife hypertension (ages 40–65) appears to matter more than late-life hypertension. In fact, aggressively lowering blood pressure in a frail 85-year-old can cause harm through falls and hypoperfusion. Timing matters.

LDL cholesterol is the newest addition to the Lancet list. High midlife LDL is now considered a distinct contributor to dementia risk beyond its stroke effects.

Diabetes and insulin resistance: Type 2 diabetes roughly increases dementia risk by 50–100% depending on the cohort. The mechanisms include microvascular damage, chronic inflammation, and impaired cerebral insulin signaling.

Practical targets to discuss with your physician:

• Blood pressure: ideally <130/80 in midlife, individualized after 80
• LDL: target set by your overall cardiovascular risk, not a universal number
• HbA1c: <5.7% ideal; if you are prediabetic, that is a treatable window
• Waist circumference: a better metabolic signal than BMI alone

3. Move Your Body — And Structure Beats Good Intentions

Physical inactivity accounts for approximately 2% of preventable dementia globally. The mechanistic story is solid: exercise increases cerebral blood flow, elevates BDNF (brain-derived neurotrophic factor), supports hippocampal volume, improves insulin sensitivity, and reduces systemic inflammation.

The US POINTER trial (Baker et al., JAMA, 2025) is the most important recent finding in this space, and it deserves a careful reading. Over two years, more than 2,000 sedentary adults aged 60–79 at elevated risk were randomized to a structured multidomain program (facilitated exercise sessions, peer support, coaching, adherence tracking, MIND-diet guidance, cognitive challenge, and cardiovascular monitoring) versus a self-guided program with the same goals but no scaffolding.

Both groups improved cognitively over two years, exceeding expected age-related trajectories. But the structured arm improved significantly more, and benefits were consistent across age, sex, race and ethnicity, baseline cardiovascular health, and APOE ε4 status.

The clinical lesson is not “exercise works” — we knew that. It is that accountability infrastructure is part of the active ingredient. Telling a patient to walk more produces less benefit than enrolling them in something with a schedule, a group, and someone who notices when they don’t show up.

Practical prescription:

• 150 minutes weekly of moderate aerobic activity (brisk walking counts — you should be able to talk but not sing), or 75 minutes vigorous
• Resistance training twekly of moderate aerobic activity (brisk walking counts — you should be able to talk but not sing), or 75 minutes vigorous
• Resistance training tw excellent here) — falls cause traumatic brain injury, itself a risk factor
• Break up sitting: prolonged sedentary time is an independent risk factor even in people who exercise

The 8-year Women Who Walk study cited in older articles (Yaffe et al., ~6,000 women aged 65+) is real and directionally correct, but it is observational and now decades old. US POINTER is the stronger citation.

4. Eat for Your Arteries — Not for a Miracle

Here I need to correct something that appears in nearly every article on this topic, including the version I was asked to revise.

The MIND diet (a hybrid of Mediterranean and DASH eating patterns, emphasizing leafy greens, berries, nuts, whole grains, fish, and olive oil) has strong observational support. Cohort studies consistently associate higher MIND adherence with slower cognitive decline.

Then it was tested properly. The MIND Diet Trial (Barnes et al., NEJM, 2023) randomized 604 participants to the MIND diet with mild caloric restriction versus a control diet, also with mild caloric restriction, over three years. Result: both groups showed modest cognitive improvement, with no statistically significant difference between them. Brain MRI outcomes likewise showed no meaningful difference.

What does that mean? Three honest interpretations, all partly true:

1. Three years may be too short to detect an effect on a 20-year disease process.
2. The control diet was itself a reasonable diet with weight loss — this was a comparison of good versus slightly better, not good versus terrible.
3. The observational signal may have been partly confounded by the fact that health-conscious people do many healthy things at once.

So what should you actually eat? A Mediterranean-pattern diet remains the right recommendation — but the justification shifts. It has robust evidence for reducing hypertension, LDL, diabetes, and stroke, and those are established dementia risk factors. You eat this way to protect your vasculature, which protects your brain. That is a defensible mechanism, not magical thinking.

The pattern:

• Vegetables at most meals; leafy greens most days
• Berries several times weekly
• Fish twice weekly (oily fish preferred)
• Nuts and legumes as protein staples
• Extra virgin olive oil as your primary fat
• Whole grains over refined
• Minimal processed meat, ultra-processed food, added sugar, and sugary drinks

On the homocysteine question raised in the original article: elevated homocysteine is indeed associated with dementia risk, and folate, B6, and B12 lower it. But lowering homocysteine with B vitamins has not reliably improved cognitive outcomes in randomized trials. Homocysteine may be a marker of risk rather than a cause of it. Correcting a documented B12 deficiency is genuinely important — B12 deficiency causes a reversible cognitive impairment that must be ruled out in any memory workup. Taking B vitamins with normal levels, in hopes of preventing Alzheimer’s, is not supported.

Also worth noting: the original article listed “red meat, potatoes, and any fruit except citrus” as foods to increase. That is not a brain-health recommendation, and high processed red meat intake is associated with increased dementia risk.

5. Sleep — And Get Sleep Apnea Diagnosed

Sleep is absent from most Persian-language articles on this topic, which is a significant omission.

During deep non-REM sleep, the brain’s glymphatic system clears metabolic waste — including amyloid-beta — far more efficiently than during waking hours. Controlled sleep-deprivation studies in humans show measurable increases in CSF amyloid-beta after a single night of disrupted sleep. Chronically short sleep (persistently under six hours in midlife) is associated with higher dementia risk in large cohorts including Whitehall II.

Obstructive sleep apnea deserves specific attention. It causes repeated nocturnal hypoxia, fragments deep sleep, and raises blood pressure — three separate pathways to cognitive harm. It is common, frequently undiagnosed, and treatable. If you snore heavily, wake unrefreshed, have witnessed breathing pauses, or fall asleep during the day, ask for a sleep study.

Two cautions: the relationship between sleep and dementia is bidirectional — early Alzheimer’s disrupts sleep, so new-onset sleep disturbance in an older adult warrants evaluation rather than just a sleep aid. And sedative-hypnotics, particularly benzodiazepines and anticholinergic sleep medications, carry their own cognitive risks in older adults. Treat the cause, not the symptom.

Practical: 7–8 hours, consistent schedule including weekends, dark and cool room, no screens for an hour before bed, caffeine cutoff by early afternoon, alcohol avoided near bedtime (it fragments sleep architecture even when it speeds sleep onset).

6. Stay Cognitively and Socially Engaged — With Realistic Expectations

The “cognitive reserve” hypothesis holds that richer neural networks tolerate more pathology before symptoms emerge. Autopsy studies support this: some people die with substantial Alzheimer’s pathology and no clinical dementia during life, and higher education and occupational complexity predict this resilience.

What the evidence supports: Sustained, effortful, novel cognitive engagement. Learning a language. Taking up an instrument. Formal education at any age. Complex work. Serious hobbies with a learning curve.

Where expectations should be tempered: Commercial “brain training” apps reliably improve performance on the trained task and show limited transfer to general cognition or real-world function. The ACTIVE trial found some durable benefits from specific reasoning and speed training, but the effects were narrow. Crossword puzzles and Sudoku are fine — I do not want to talk anyone out of enjoying them — but doing your 3,000th crossword is not novel cognitive work. Learning to play chess when you never have would be.

Social engagement may matter more than puzzles. Social isolation is a distinct factor on the Lancet list. Conversation is arguably the most cognitively demanding routine activity humans perform: it requires real-time language processing, memory, theory of mind, emotional regulation, and inhibition, all simultaneously. Loneliness also elevates cortisol and inflammatory markers.

The original article’s claim that homebound seniors have “roughly twice the risk” compared to those who travel more overstates a modest observational association. The direction is right; the number is not reliable, and reverse causation is a real concern — early cognitive decline reduces travel.

Practical: Regular in-person contact, ideally weekly or more. Volunteering. Group classes rather than solo apps. Caregiving and community roles. Maintaining hearing and vision, because both are prerequisites for social participation — which is why they cluster with this section.

7. Stop Smoking, Moderate Alcohol, Protect Your Head

Smoking contributes to dementia through vascular damage, oxidative stress, and inflammation. Risk declines after cessation — former smokers approach never-smoker risk over time. There is no age at which quitting stops being worthwhile.

Alcohol: the guidance here has genuinely changed. The old “moderate drinking protects the brain” story has largely collapsed under better methodology. Much of the apparent benefit came from including former heavy drinkers who quit due to illness in the “abstainer” group. Current evidence, including Mendelian randomization studies, suggests no clearly protective dose. Heavy drinking (>21 units weekly) is a well-established risk factor, and MRI studies show dose-dependent brain volume reduction extending into what was considered moderate consumption. The safest amount for brain health is likely zero; the practical recommendation is to minimize.

Traumatic brain injury is on the Lancet list and often overlooked. Helmets for cycling and motorcycling. Seatbelts. Fall prevention in older adults — home lighting, removing loose rugs, treating orthostatic hypotension, reviewing medications that impair balance, and building lower-body strength.

Air pollution also belongs here. Long-term PM2.5 exposure is associated with dementia risk. Individual mitigation is limited but real: indoor HEPA filtration, avoiding exercise outdoors during high-pollution periods, and adequate ventilation when cooking with gas.

8. Treat Depression, and Treat Vision Loss

Depression appears on the Lancet list, though the causal direction is genuinely complicated. Late-life depression can be a prodromal symptom of dementia rather than a cause. But midlife depression predicts later dementia even with long lag times, and depression drives inactivity, isolation, poor sleep, and reduced self-care — all downstream risk factors. Depression is worth treating for its own sake; the potential cognitive benefit is a bonus.

Note that some medications used for psychiatric and urological conditions carry strong anticholinergic burden, which is independently associated with dementia risk in older adults. Periodic medication review with a pharmacist or physician is a genuinely underused intervention.

Untreated vision loss was added to the Lancet list in 2024 (~2% attributable fraction). Cataract surgery is associated with lower subsequent dementia risk in observational data. Uncorrected refractive error, cataracts, glaucoma, and macular degeneration all reduce environmental and social input. Annual or biennial eye exams after 50; treat what is treatable.

What Does Not Work — And Why It’s Worth Saying Plainly

Recommending things without evidence is not neutral. It costs money, delays effective action, and occasionally causes harm.

Ginkgo biloba. The GEM study (DeKosky et al., JAMA, 2008) randomized 3,069 older adults to 120 mg of standardized Ginkgo biloba twice daily or placebo, with a median follow-up of 6.1 years. It did not reduce the incidence of dementia or Alzheimer’s disease. The GuidAge trial in Europe found the same. This is a well-tested, negative result — not an open question. Ginkgo also inhibits platelet aggregation and interacts with anticoagulants.

Huperzine A. A cholinesterase inhibitor sold as a supplement. Small trials of variable quality; no adequate prevention evidence; unregulated dosing with real cholinergic side-effect potential.

Ginseng, Bacopa monnieri, lemon balm (Melissa officinalis), vinpocetine, and periwinkle extracts. Some show modest short-term effects on attention or mood in small studies. None has evidence for preventing Alzheimer’s disease. Vinpocetine is notable because it is not approved as a drug in the US or EU, has been found in inconsistent amounts in commercial products, and is contraindicated in pregnancy.

Vitamin E, high-dose B vitamins, and omega-3 supplements for prevention: negative or inconsistent in randomized trials. High-dose vitamin E (>400 IU/day) has been associated with increased all-cause mortality. Eating fish is supported; taking fish oil capsules for dementia prevention is not.

Coconut oil, “ no credible prevention evidence.

A note on turmeric/curcumin: despite strong mechanistic and epidemiological interest, randomized trials in humans have been disappointing, largely due to poor bcurcumin:** despite strong mechanistic and epidemiological interest, randomized trials in humans have been disappointing, largely due to poor bioavailability. Using turmeric in cooking is entirely reasonable. Buying high-dose curcumin to prevent Alzheimer’s is not evidence-based.

Acupuncture, massage, and aromatherapy: these can meaningfully improve wellbeing, agitation, and quality of life in people already living with dementia — that is a legitimate role in care. There is no evidence they prevent the disease. Conflating comfort care with prevention misleads readers.

The most important correction: cholinesterase inhibitors and memantine are not preventive drugs.

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors. Memantine is an NMDA receptor antagonist. All four are symptomatic treatments, licensed for people who already have a diagnosis. They modestly improve cognitive and functional scores for a period. They do not alter the underlying disease process, and they are not indicated for people without dementia — including people with a family history who are worried.

Trials of donepezil in mild cognitive impairment showed no durable prevention of progression. Prescribing these drugs to an asymptomatic person exposes them to bradycardia, syncope, GI side effects, and cost, with no expected benefit. The original article’s suggestion that a neurologist can “prescribe these to help prevent Alzheimer’s progression” is a meaningful clinical error, and I want to be direct about it.

Where the New Anti-Amyloid Drugs Fit

Since 2023, monoclonal antibodies targeting amyloid-beta — lecanemab (Leqembi) and donanemab (Kisunla) — have been approved in the US and several other jurisdictions. They represent the first therapies shown to modify the disease process rather than only the symptoms.

What they are: infused antibodies that clear amyloid plaques, producing a modest slowing of clinical decline (roughly 25–35% relative slowing over 18 months in pivotal trials — a real but clinically modest absolute difference).

What they are not: preventive. They are indicated for confirmed early symptomatic Alzheimer’s — mild cognitive impairment or mild dementia with biomarker-confirmed amyloid pathology. They require infusion infrastructure, genotyping considerations, and serial MRI monitoring for ARIA (amyloid-related imaging abnormalities: brain edema and microhemorrhage), which is common and occasionally serious. Availability varies substantially by country, and access in Iran and much of the region is currently limited.

Prevention trials in asymptomatic amyloid-positive individuals (AHEAD 3-45, TRAILBLAZER-ALZ 3) are ongoing. Their results will matter enormously. They are not in yet.

Also relevant and more immediately practical: blood-based biomarkers (p-tau217 in particular) have advanced rapidly and are beginning to enter clinical use. They will change how early and how accurately Alzheimer’s is diagnosed. They are diagnostic tools, not prevention.

Building a Realistic Plan

Prevention advice fails when it is a list of 40 items. Here is what I would actually prioritize, by decade.

In your 40s and 50s — the highest-leverage window. Get blood pressure, lipids, and HbA1c measured and treated to target. Establish an exercise habit you will keep for 30 years. Get a baseline audiogram. Address heavy drinking and smoking now. Treat sleep apnea. Protect your head.

In your 60s. Everything above, plus: treat hearing and vision loss promptly rather than adapting to it. Build social structure deliberately, especially around retirement, which removes cognitive and social scaffolding at once. Add resistance and balance training. Review your medication list for anticholinergic burden.

In your 70s and beyond. Maintain function above all — mobility, hearing, vision, social connection, nutrition. Prevent falls. Blood pressure targets should be individualized and relaxed with frailty. Stay engaged in something that requires you.

The one-sentence version: what protects your heart protects your brain, and staying connected to other people is not a soft recommendation.

When to See a Doctor

Seek evaluation promptly — not “keep an eye on it” — for any of the following:

• Repetitive questioning or forgetting rec
• Word-finding difficulty that interrupts speech, or substituting wrong words
• Poor judgment, uncharacteristic financial decisions, or new susceptibility to scams
• Personality or behavior change: apathy, withdrawal, disinhibition, new suspiciousness
• Misplacing items in implausible locations, or accusing others of theft
• Concerns raised by family that the person themselves dismisses — reduced insight is itself a warning sign

Two points on urgency. First, several causes of cognitive impairment are reversible: B12 deficiency, hypothyroidism, depression, normal-pressure hydrocephalus, subdural hematoma, medication effects, sleep apnea, and alcohol-related impairment. These need to be identified, and they are found through a proper workup — history, cognitive testing, bloodwork, and imaging where indicated.

Second, the newer disease-modifying therapies are only useful at the earliest symptomatic stage. Waiting until the diagnosis is obvious can close that window. Early evaluation is more actionable now than it was five years ago.

Start with a primary care physician, who can order initial labs and screening. Referral to a neurologist, geriatrician, or memory clinic follows if indicated. If you have a family history of early-onset dementia across multiple generations, ask specifically about genetic counseling — that is a different pathway with different implications, including for family members.

Frequently Asked Questions

At what age should I start prevention?

Midlife — roughly 40 to 50 — is when the modifiable risk factors do most of their damage, and therefore when intervention has the most leverage. But there is no age at which it becomes pointless. US POINTER enrolled 60–79-year-olds and showed benefit within two years. Earlier is better; now is better than later.

Can traditional or herbal medicine prevent Alzheimer’s?

No herbal preparation has been shown in adequate randomized trials to prevent Alzheimer’s disease. Ginkgo biloba was tested in over 3,000 people for more than six years and did not reduce dementia incidence. Some traditional practices — massage, aromatherapy, structured movement like tai chi — have a legitimate role in improving wellbeing and reducing agitation for people already living with dementia, and tai chi genuinely helps balance and fall prevention. That is worth something. It is not prevention, and the two should not be conflated. Also: herbal products interact with prescription drugs, and several are poorly standardized. Tell your physician what you are taking.

What is the single best prevention strategy?

There isn’t one, and the honest answer is that risk reduction is additive. If forced to rank by evidence and effect size: control your blood pressure and vascular risk factors from midlife, treat hearing loss, exercise regularly with structure, and maintain genuine social connection. The Lancet Commission’s 45% figure comes from addressing factors collectively, not from any single one.

If I have the APOE ε4 gene, is prevention futile?

No. In US POINTER, lifestyle intervention benefits were consistent across ε4 carriers and non-carriers. ε4 shifts your baseline probability; it does not remove your ability to change trajectory. Routine ε4 testing outside research or specific clinical contexts is generally not recommended, partly because it does not change management — the advice is the same either way.

Do memory supplements help?

There is no supplement with credible evidence for preventing Alzheimer’s disease. Correcting a documented deficiency — B12 in particular, and vitamin D where deficient — is legitimate medicine. Taking supplements without a deficiency is not. Some carry real risks: high-dose vitamin E has been associated with increased mortality, and ginkgo affects bleeding risk.

Is Alzheimer’s inherited?

Rarely in the deterministic sense. Mutations in APP, PSEN1, or PSEN2 cause autosomal dominant Alzheimer’s and account for well under 1% of cases, typically with onset before 60. Having a parent or sibling with late-onset Alzheimer’s roughly doubles your risk through a mix of shared genetics and shared environment — a meaningful increase, but far from a certainty, and the modifiable factors still apply.

Does forgetting names mean I’m developing Alzheimer’s?

Almost always no. Age-related slowing of retrieval is normal — you forget the name and it comes back later. The concerning pattern is forgetting the event, repeating yourself without awareness, or losing the ability to performieval is normal — you forget the name and it comes back later. The concerning pattern is forgetting the event, repeating yourself without awareness, or losing the ability to perform reassuring.

Do crossword puzzles prevent Alzheimer’s?

They contribute to cognitive engagement, but novelty and difficulty appear to matter more than repetition. If you have done crosswords for 30 years, they are no longer a cognitive challenge. Learning something genuinely new — an instrument, a language, a skill — is a better use of the same time. Social activities that require real-time interaction may be better still.

Key References

1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572–628.
2. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA. 2025.
3. Barnes LL, Dhana K, Liu X, et al. Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons. New England Journal of Medicine. 2023;389(7):602–611.
4. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. The Lancet. 2023;402(10404):786–797.
5. SPRINT MIND Investigators. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019;321(6):553–561.
6. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial (GEM Study). JAMA. 2008;300(19):2253–2262.
7. Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia. 2025.
8. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. NEJM. 2023;388(1):9–21.
9. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease (TRAILBLAZER-ALZ 2). JAMA. 2023;330(6):512–527.
10. World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: WHO.

---

Medical disclaimer: This article is for general education and does not replace individual medical assessment. Do not start, stop, or change any medication or supplement based on this content. Diagnostic evaluation of memory symptoms requires in-person clinical assessment, and target values for blood pressure, lipids, and glucose must be individualized — particularly in adults over 80 or those with frailty or multiple conditions.